Search Results - "Adam, Januszewski"

258 HORIZON-01: a phase I–III platform study evaluating the efficacy and safety of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non-small cell lung cancer (NSCLC).

Authors: Sanjay, Popat Adam, Januszewski Laura, Cove-Smith et al.

Source: Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.

125 Evaluation of Patients Experience of Receiving Immunotherapy (IO).

Authors: Bing, Smith Adam, Januszewski John, Leggett et al.

Source: Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.

263 The use of 3,4-Diaminopyridine (3,4-DAP) in the management of life-threatening paraneoplastic Lambert Easton Myasthenic Syndrome (LEMS) – A case report.

Authors: Louis, Kennedy Tanith, Westerman Balwinder, Kolotia et al.

Source: Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.

112 Real-World Outcomes in Patients treated with First-line Anti-PD(L)-1 Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer - A Single Tertiary Centre Experience.

Authors: Radhika, Patel Akashi, Alam Tanith, Westerman et al.

Source: Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.

98 Hospitalisation Rates following Systemic Anti-Cancer Treatments for Patients with Non-Small Cell Lung Cancer.

Authors: Pinkie, Chambers Ofran, Almossawi Luke, Steventon et al.

Source: Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.

92 Clinical impact and real-world UK multi-center experience of neoadjuvant chemoimmunotherapy for resectable NSCLC.

Authors: Marina, Milic Maggie, Cheung Lakov, Bolnykh et al.

Source: Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.

19 The development of a patient engagement intervention to improve lung cancer patients' and carers' experience of and engagement in their recommended lung cancer care pathway in rural, coastal, and urban settings.

Authors: Samuel, Cooke Lucy, Mitchinson Samantha, Quaife et al.

Source: Lung Cancer (01695002). 2025 Supplement 1, Vol. 200, pN.PAG-N.PAG. 1p.